#METABOLOMICS WORKBENCH vadim.yanshole@tomo.nsc.ru_20240916_210258 DATATRACK_ID:5197 STUDY_ID:ST003506 ANALYSIS_ID:AN005756 PROJECT_ID:PR002152 VERSION 1 CREATED_ON October 1, 2024, 2:14 pm #PROJECT PR:PROJECT_TITLE Metabolomics of breast cancer-related lymphedema PR:PROJECT_SUMMARY Diagnosing and treating diseases such as breast cancer-related lymphedema (BCRL) PR:PROJECT_SUMMARY is challenging due to a limited understanding of the underlying mechanisms. PR:PROJECT_SUMMARY Despite recent advancements, BCRL significantly impacts patients' quality of PR:PROJECT_SUMMARY life, as current treatments only manage symptoms. Leveraging modern PR:PROJECT_SUMMARY high-throughput omics technologies, particularly metabolomics, holds potential PR:PROJECT_SUMMARY to address these challenges. PR:INSTITUTE International Tomography Center SB RAS PR:LABORATORY Laboratory of Proteomics and Metabolomics PR:LAST_NAME Yanshole PR:FIRST_NAME Vadim PR:ADDRESS Institutskaya 3a, Novosibirsk, Russia PR:EMAIL vadim.yanshole@tomo.nsc.ru PR:PHONE +73833303136 PR:FUNDING_SOURCE Russian Science Foundation, grant number 23-25-00462 PR:CONTRIBUTORS Vadim V. Yanshole, Lyudmila V. Yanshole, Daria S. Gorina, Nataliya A. Osik, PR:CONTRIBUTORS Vadim V. Nimaev, and Yuri P. Tsentalovich #STUDY ST:STUDY_TITLE Comparison of serum and interstitial fluid from patients with breast ST:STUDY_TITLE cancer-related lymphedema and healthy control subjects with NMR-based ST:STUDY_TITLE metabolomics ST:STUDY_SUMMARY Diagnosing and treating diseases such as breast cancer-related lymphedema (BCRL) ST:STUDY_SUMMARY is challenging due to a limited understanding of the underlying mechanisms. ST:STUDY_SUMMARY Despite recent advancements, BCRL significantly impacts patients' quality of ST:STUDY_SUMMARY life, as current treatments only manage symptoms. Leveraging modern ST:STUDY_SUMMARY high-throughput omics technologies, particularly metabolomics, holds potential ST:STUDY_SUMMARY to address these challenges. Metabolomics offers insights into dynamic changes ST:STUDY_SUMMARY influenced by internal and external factors, aiding in understanding the tissue ST:STUDY_SUMMARY physiology and detecting pathological conditions. The investigation of ST:STUDY_SUMMARY metabolomic biomarkers holds promise for early lymphedema diagnosis and ST:STUDY_SUMMARY personalized treatment. The deposited dataset represent high-resolution nuclear ST:STUDY_SUMMARY magnetic resonance (NMR) data for patients' blood serum and interstitial fluid, ST:STUDY_SUMMARY obtained after breast cancer treatment and with diagnosed BCRL, as well as ST:STUDY_SUMMARY control samples. Simple statistical analysis yielded increased concentrations of ST:STUDY_SUMMARY pyruvate, citrate, 2-ketoisovalerate, ketoleucine, 3-methyl-2-oxovalerate, ST:STUDY_SUMMARY tryptophan, and ascorbate in serum samples from patients with lymphedema. This ST:STUDY_SUMMARY dataset can aid in identifying early-stage lymphedema biomarkers and deepen ST:STUDY_SUMMARY insights into lymphatic system function thus leading to the development of ST:STUDY_SUMMARY effective diagnostic and therapeutic tools. ST:INSTITUTE International Tomography Center SB RAS ST:LABORATORY Laboratory of Proteomics and Metabolomics ST:LAST_NAME Yanshole ST:FIRST_NAME Vadim ST:ADDRESS Institutskaya 3a, Novosibirsk, Russia ST:EMAIL vadim.yanshole@tomo.nsc.ru ST:PHONE +73833303136 ST:NUM_GROUPS 3 ST:TOTAL_SUBJECTS 34 #SUBJECT SU:SUBJECT_TYPE Human SU:SUBJECT_SPECIES Homo sapiens SU:TAXONOMY_ID 9606 SU:AGE_OR_AGE_RANGE 50-79 SU:GENDER Female #SUBJECT_SAMPLE_FACTORS: SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data SUBJECT_SAMPLE_FACTORS K1 K1 Sample source:Blood serum | Group:Control Diseases=Coxarthrosis; RAW_FILE_NAME(Raw NMR file)=K1.zip SUBJECT_SAMPLE_FACTORS K2 K2 Sample source:Blood serum | Group:Control Diseases=Coxarthrosis; RAW_FILE_NAME(Raw NMR file)=K2.zip SUBJECT_SAMPLE_FACTORS K3 K3 Sample source:Blood serum | Group:Control Diseases=Gonarthrosis; RAW_FILE_NAME(Raw NMR file)=K3.zip SUBJECT_SAMPLE_FACTORS K4 K4 Sample source:Blood serum | Group:Control Diseases=Solitary renal cyst; RAW_FILE_NAME(Raw NMR file)=K4.zip SUBJECT_SAMPLE_FACTORS K5 K5 Sample source:Blood serum | Group:Control Diseases=Gonarthrosis; RAW_FILE_NAME(Raw NMR file)=K5.zip SUBJECT_SAMPLE_FACTORS K7 K7 Sample source:Blood serum | Group:Control Diseases=Aseptic loosening of knee joint replacements; RAW_FILE_NAME(Raw NMR file)=K7.zip SUBJECT_SAMPLE_FACTORS K8 K8 Sample source:Blood serum | Group:Control Diseases=Gonarthrosis; RAW_FILE_NAME(Raw NMR file)=K8.zip SUBJECT_SAMPLE_FACTORS K9 K9 Sample source:Blood serum | Group:Control Diseases=Aseptic loosening of knee joint replacements; RAW_FILE_NAME(Raw NMR file)=K9.zip SUBJECT_SAMPLE_FACTORS K10 K10 Sample source:Blood serum | Group:Control Diseases=Gonarthrosis; RAW_FILE_NAME(Raw NMR file)=K10.zip SUBJECT_SAMPLE_FACTORS K11 K11 Sample source:Blood serum | Group:Control Diseases=Stage 2 hypertension; RAW_FILE_NAME(Raw NMR file)=K11.zip SUBJECT_SAMPLE_FACTORS K12 K12 Sample source:Blood serum | Group:Control Diseases=Gonarthrosis; RAW_FILE_NAME(Raw NMR file)=K12.zip SUBJECT_SAMPLE_FACTORS K13 K13 Sample source:Blood serum | Group:Control Diseases=Articulating spacer; RAW_FILE_NAME(Raw NMR file)=K13.zip SUBJECT_SAMPLE_FACTORS 245c 245c Sample source:Blood serum | Group:Lymphedema Diseases=Lymphedema; RAW_FILE_NAME(Raw NMR file)=245c.zip SUBJECT_SAMPLE_FACTORS 248c 248c Sample source:Blood serum | Group:Lymphedema Diseases=Lymphedema; RAW_FILE_NAME(Raw NMR file)=248c.zip SUBJECT_SAMPLE_FACTORS 249c 249c Sample source:Blood serum | Group:Lymphedema Diseases=Lymphedema; RAW_FILE_NAME(Raw NMR file)=249c.zip SUBJECT_SAMPLE_FACTORS 250c 250c Sample source:Blood serum | Group:Lymphedema Diseases=Lymphedema; RAW_FILE_NAME(Raw NMR file)=250c.zip SUBJECT_SAMPLE_FACTORS 252c 252c Sample source:Blood serum | Group:Lymphedema Diseases=Lymphedema; RAW_FILE_NAME(Raw NMR file)=252c.zip SUBJECT_SAMPLE_FACTORS 253c 253c Sample source:Blood serum | Group:Lymphedema Diseases=Lymphedema; RAW_FILE_NAME(Raw NMR file)=253c.zip SUBJECT_SAMPLE_FACTORS 257c 257c Sample source:Blood serum | Group:Lymphedema Diseases=Lymphedema; RAW_FILE_NAME(Raw NMR file)=257c.zip SUBJECT_SAMPLE_FACTORS 258c 258c Sample source:Blood serum | Group:Lymphedema Diseases=Lymphedema; RAW_FILE_NAME(Raw NMR file)=258c.zip SUBJECT_SAMPLE_FACTORS 259c 259c Sample source:Blood serum | Group:Lymphedema Diseases=Lymphedema; RAW_FILE_NAME(Raw NMR file)=259c.zip SUBJECT_SAMPLE_FACTORS s251 s251 Sample source:Blood serum | Group:Lymphedema Diseases=Lymphedema; RAW_FILE_NAME(Raw NMR file)=s251.zip SUBJECT_SAMPLE_FACTORS s253 s253 Sample source:Blood serum | Group:Lymphedema Diseases=Lymphedema; RAW_FILE_NAME(Raw NMR file)=s253.zip SUBJECT_SAMPLE_FACTORS s293 s293 Sample source:Blood serum | Group:Lymphedema Diseases=Lymphedema; RAW_FILE_NAME(Raw NMR file)=s293.zip SUBJECT_SAMPLE_FACTORS s294 s294 Sample source:Blood serum | Group:Lymphedema Diseases=Lymphedema; RAW_FILE_NAME(Raw NMR file)=s294.zip SUBJECT_SAMPLE_FACTORS s299 s299 Sample source:Blood serum | Group:Lymphedema Diseases=Lymphedema; RAW_FILE_NAME(Raw NMR file)=s299.zip SUBJECT_SAMPLE_FACTORS s303 s303 Sample source:Blood serum | Group:Lymphedema Diseases=Lymphedema; RAW_FILE_NAME(Raw NMR file)=s303.zip SUBJECT_SAMPLE_FACTORS s313 s313 Sample source:Blood serum | Group:Lymphedema Diseases=Lymphedema; RAW_FILE_NAME(Raw NMR file)=s313.zip SUBJECT_SAMPLE_FACTORS s315 s315 Sample source:Blood serum | Group:Lymphedema Diseases=Lymphedema; RAW_FILE_NAME(Raw NMR file)=s315.zip SUBJECT_SAMPLE_FACTORS s318 s318 Sample source:Blood serum | Group:Lymphedema Diseases=Lymphedema; RAW_FILE_NAME(Raw NMR file)=s318.zip SUBJECT_SAMPLE_FACTORS s330 s330 Sample source:Blood serum | Group:Lymphedema Diseases=Lymphedema; RAW_FILE_NAME(Raw NMR file)=s330.zip SUBJECT_SAMPLE_FACTORS s336 s336 Sample source:Blood serum | Group:Lymphedema Diseases=Lymphedema; RAW_FILE_NAME(Raw NMR file)=s336.zip SUBJECT_SAMPLE_FACTORS s339 s339 Sample source:Blood serum | Group:Lymphedema Diseases=Lymphedema; RAW_FILE_NAME(Raw NMR file)=s339.zip SUBJECT_SAMPLE_FACTORS s345 s345 Sample source:Blood serum | Group:Lymphedema Diseases=Lymphedema; RAW_FILE_NAME(Raw NMR file)=s345.zip SUBJECT_SAMPLE_FACTORS 245c 245t Sample source:Interstitial fluid | Group:Lymphedema Diseases=Lymphedema; RAW_FILE_NAME(Raw NMR file)=245t.zip SUBJECT_SAMPLE_FACTORS 248c 248t Sample source:Interstitial fluid | Group:Lymphedema Diseases=Lymphedema; RAW_FILE_NAME(Raw NMR file)=248t.zip SUBJECT_SAMPLE_FACTORS 249c 249t Sample source:Interstitial fluid | Group:Lymphedema Diseases=Lymphedema; RAW_FILE_NAME(Raw NMR file)=249t.zip SUBJECT_SAMPLE_FACTORS 250c 250t Sample source:Interstitial fluid | Group:Lymphedema Diseases=Lymphedema; RAW_FILE_NAME(Raw NMR file)=250t.zip SUBJECT_SAMPLE_FACTORS 252c 252t Sample source:Interstitial fluid | Group:Lymphedema Diseases=Lymphedema; RAW_FILE_NAME(Raw NMR file)=252t.zip SUBJECT_SAMPLE_FACTORS 253c 253t Sample source:Interstitial fluid | Group:Lymphedema Diseases=Lymphedema; RAW_FILE_NAME(Raw NMR file)=253t.zip SUBJECT_SAMPLE_FACTORS 257c 257t Sample source:Interstitial fluid | Group:Lymphedema Diseases=Lymphedema; RAW_FILE_NAME(Raw NMR file)=257t.zip SUBJECT_SAMPLE_FACTORS 258c 258t Sample source:Interstitial fluid | Group:Lymphedema Diseases=Lymphedema; RAW_FILE_NAME(Raw NMR file)=258t.zip SUBJECT_SAMPLE_FACTORS 259c 259t Sample source:Interstitial fluid | Group:Lymphedema Diseases=Lymphedema; RAW_FILE_NAME(Raw NMR file)=259t.zip #COLLECTION CO:COLLECTION_SUMMARY The investigations were conducted in accordance with the principles outlined in CO:COLLECTION_SUMMARY the Declaration of Helsinki 2008 CO:COLLECTION_SUMMARY (https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/doh-oct2008/, CO:COLLECTION_SUMMARY accessed on 01.08.2024), which delineate ethical principles for medical research CO:COLLECTION_SUMMARY involving human subjects. Ethical approval was obtained from the International CO:COLLECTION_SUMMARY Tomography Center SB RAS ( ECITC-2020-12 from 16.12.2020) and the Research CO:COLLECTION_SUMMARY Institute of Clinical and Experimental Lymphology – Branch of the Institute of CO:COLLECTION_SUMMARY Cytology and Genetics SB RAS ( 159 from 20.07.2020). Written informed consent CO:COLLECTION_SUMMARY was obtained from all patients after a thorough explanation of the study's CO:COLLECTION_SUMMARY nature and potential consequences. No special permission from national or local CO:COLLECTION_SUMMARY authorities was required. Blood (n=22) and interstitial fluid (n=9) samples were CO:COLLECTION_SUMMARY collected from patients who had previously undergone breast cancer treatment and CO:COLLECTION_SUMMARY who subsequently developed and were diagnosed with BCRL (n=22, age 69.6 ± 3.4 CO:COLLECTION_SUMMARY years). Control blood samples (n=12, age 63.7 ± 6.5 years) were collected from CO:COLLECTION_SUMMARY age-matched patients without diagnosed breast can-cer and without lymphedema. CO:COLLECTION_SUMMARY Peripheral blood was obtained from the ulnar vein in the morning after overnight CO:COLLECTION_SUMMARY fasting under aseptic conditions into a vacutainer containing a coagulation CO:COLLECTION_SUMMARY activator. Within 10-15 minutes of collection, the blood samples were CO:COLLECTION_SUMMARY centrifuged (3000×g, 10 min), and the plasma obtained was transferred into CO:COLLECTION_SUMMARY separate Eppendorf vials. We have developed a method for collecting interstitial CO:COLLECTION_SUMMARY fluid from the subcutaneous tissue of the affected area from the patients with CO:COLLECTION_SUMMARY limb lymphedema. For this purpose, an ultrasound examination of the affected CO:COLLECTION_SUMMARY limb was performed using a 5 MHz and 10 MHz linear array probe. Areas of CO:COLLECTION_SUMMARY interstitial fluid accumulation were identified and marked. At these areas, the CO:COLLECTION_SUMMARY skin was punctured with a 27G needle and the interstitial fluid that appeared at CO:COLLECTION_SUMMARY the puncture site was collected using a 22G plastic catheter and transferred CO:COLLECTION_SUMMARY into clean Eppendorf vials. The vials with biofluid samples were immediately CO:COLLECTION_SUMMARY frozen and stored at -70°C until analysis. CO:SAMPLE_TYPE Blood serum; Interstitial fluid #TREATMENT TR:TREATMENT_SUMMARY Not applicable #SAMPLEPREP SP:SAMPLEPREP_SUMMARY Sample Preparation For the preparation of extracts from blood serum for SP:SAMPLEPREP_SUMMARY metabolomic measurements, we adhered to a standard protocol. Serum volume was SP:SAMPLEPREP_SUMMARY 300 μl, ISF volume varied from 50 to 200 μl. Briefly, after thawing human SP:SAMPLEPREP_SUMMARY blood plasma, we removed the clot from the vial, thus obtaining blood serum. SP:SAMPLEPREP_SUMMARY Then, we added 300 μL of H2O, 600 μL of cold (-20 °C) methanol and 600 μL of SP:SAMPLEPREP_SUMMARY cold (-20 °C) chloroform to 300 µL of serum. The mixture was then stirred on a SP:SAMPLEPREP_SUMMARY shaker at +4 °C for 15 minutes, followed by incubation at -20 °C for 30 SP:SAMPLEPREP_SUMMARY minutes. Subsequently, the mixture was centrifuged at 16,100×g for 30 minutes SP:SAMPLEPREP_SUMMARY at +4 °C. Upon centrifugation, the mixture separated into two immiscible SP:SAMPLEPREP_SUMMARY phases. The upper water-methanol phase was collected and vacuum dried overnight. SP:SAMPLEPREP_SUMMARY NMR Measurements The dried extracts were dissolved in 600 µL of D2O containing SP:SAMPLEPREP_SUMMARY 20 µM of DSS (sodium 4,4-dimethyl-4-silapentane-1-sulfonic acid) as an internal SP:SAMPLEPREP_SUMMARY standard and 50 mM of deuterated phosphate buffer (pH 7.2). The 1H NMR SP:SAMPLEPREP_SUMMARY measurements were conducted at the Center of Collective Use "Mass Spectrometric SP:SAMPLEPREP_SUMMARY Investigations" SB RAS, using an AVANCE III HD 700 MHz NMR spectrometer (Bruker SP:SAMPLEPREP_SUMMARY BioSpin, Rheinstetten, Germany). NMR spectra for each sample were acquired in a SP:SAMPLEPREP_SUMMARY standard 5 mm glass NMR tube using a 5 mm TXI ATMA NMR probe. We used 70-degree SP:SAMPLEPREP_SUMMARY detection pulse (pulse sequence name zg) and summed 64 free induction decay SP:SAMPLEPREP_SUMMARY (FID) signals while maintaining the sample temperature at 25°C. For two ISF SP:SAMPLEPREP_SUMMARY samples with volumes below 100 µl, we collected 128 FIDs to improve the SP:SAMPLEPREP_SUMMARY signal-to-noise ratio. Prior to acquisition, low-power radiation was applied at SP:SAMPLEPREP_SUMMARY the water resonance frequency to presaturate the water signal. To allow for the SP:SAMPLEPREP_SUMMARY relaxation of all spins, a repetition time of 6 seconds was used between scans. SP:SAMPLEPREP_SUMMARY Identification and quantification of metabolites in NMR data Metabolite SP:SAMPLEPREP_SUMMARY identification was conducted by analyzing their NMR spectra, which were sourced SP:SAMPLEPREP_SUMMARY from literature, databases (HMDB, METLIN, BMRB, and SpectraBase), an in-house SP:SAMPLEPREP_SUMMARY NMR library (AMDB). Baseline processing, identification, and integration of SP:SAMPLEPREP_SUMMARY spectral NMR peaks (quantification) were performed using MestReNova v12.0 SP:SAMPLEPREP_SUMMARY (Mestrelab Research, A Coruna, Spain). In instances where NMR signal assignment SP:SAMPLEPREP_SUMMARY was not straightforward, the identification of metabolites was verified by SP:SAMPLEPREP_SUMMARY spiking extracts with commercially available standard compounds. Despite these SP:SAMPLEPREP_SUMMARY efforts, several signals in the NMR spectra remained unassigned. The metabolite SP:SAMPLEPREP_SUMMARY concentrations in samples were determined in µM by integrating NMR signals SP:SAMPLEPREP_SUMMARY relative to the internal standard DSS, and then normalized to the biofluid SP:SAMPLEPREP_SUMMARY volume. On average, 60-80 compounds were identified in samples. However, SP:SAMPLEPREP_SUMMARY quantifying some compounds was unreliable due to weak signals or overlapping SP:SAMPLEPREP_SUMMARY with other signals. The final table contains only 51 reliably identified and SP:SAMPLEPREP_SUMMARY quantified metabolites. The raw data could contain more information on as yet SP:SAMPLEPREP_SUMMARY unidentified metabolites. #ANALYSIS AN:LABORATORY_NAME Laboratory of proteomics and metabolomics #NMR NM:INSTRUMENT_NAME AVANCE III HD 700 MHz NMR spectrometer (Bruker BioSpin) NM:INSTRUMENT_TYPE FT-NMR NM:NMR_EXPERIMENT_TYPE 1D-1H NM:SPECTROMETER_FREQUENCY 700 MHz NM:NMR_PROBE 5 mm TXI ATMA NM:NMR_SOLVENT 50 mM of deuterated phosphate buffer (pH 7.2) NM:NMR_TUBE_SIZE 5 mm NM:PULSE_SEQUENCE zg NM:WATER_SUPPRESSION presat NM:TEMPERATURE 25 NM:NUMBER_OF_SCANS 64 #NMR_METABOLITE_DATA NMR_METABOLITE_DATA:UNITS uM NMR_METABOLITE_DATA_START Samples K1 K2 K3 K4 K5 K7 K8 K9 K10 K11 K12 K13 245c 248c 249c 250c 252c 253c 257c 258c 259c s251 s253 s293 s294 s299 s303 s313 s315 s318 s330 s336 s339 s345 245t 248t 249t 250t 252t 253t 257t 258t 259t Factors Sample source:Blood serum | Group:Control Sample source:Blood serum | Group:Control Sample source:Blood serum | Group:Control Sample source:Blood serum | Group:Control Sample source:Blood serum | Group:Control Sample source:Blood serum | Group:Control Sample source:Blood serum | Group:Control Sample source:Blood serum | Group:Control Sample source:Blood serum | Group:Control Sample source:Blood serum | Group:Control Sample source:Blood serum | Group:Control Sample source:Blood serum | Group:Control Sample source:Blood serum | Group:Lymphedema Sample source:Blood serum | Group:Lymphedema Sample source:Blood serum | Group:Lymphedema Sample source:Blood serum | Group:Lymphedema Sample source:Blood serum | Group:Lymphedema Sample source:Blood serum | Group:Lymphedema Sample source:Blood serum | Group:Lymphedema Sample source:Blood serum | Group:Lymphedema Sample source:Blood serum | Group:Lymphedema Sample source:Blood serum | Group:Lymphedema Sample source:Blood serum | Group:Lymphedema Sample source:Blood serum | Group:Lymphedema Sample source:Blood serum | Group:Lymphedema Sample source:Blood serum | Group:Lymphedema Sample source:Blood serum | Group:Lymphedema Sample source:Blood serum | Group:Lymphedema Sample source:Blood serum | Group:Lymphedema Sample source:Blood serum | Group:Lymphedema Sample source:Blood serum | Group:Lymphedema Sample source:Blood serum | Group:Lymphedema Sample source:Blood serum | Group:Lymphedema Sample source:Blood serum | Group:Lymphedema Sample source:Interstitial fluid | Group:Lymphedema Sample source:Interstitial fluid | Group:Lymphedema Sample source:Interstitial fluid | Group:Lymphedema Sample source:Interstitial fluid | Group:Lymphedema Sample source:Interstitial fluid | Group:Lymphedema Sample source:Interstitial fluid | Group:Lymphedema Sample source:Interstitial fluid | Group:Lymphedema Sample source:Interstitial fluid | Group:Lymphedema Sample source:Interstitial fluid | Group:Lymphedema 2S-Aminobutyric acid 33.3 33.8 33 27 22.3 24.1 30.9 25.5 26.6 30 24.3 18 18.2 20.8 26.1 11.8 40 33 20.5 34.2 19.4 42.3 22.5 14.9 29.8 24.2 27.5 29.4 21.1 47.5 16.6 15.8 42.2 36.7 9.1 24.8 24.4 10.7 36.9 21.1 17 31 21.9 2-Hydroxy-3-methylbutyric acid 6.7 15.4 6.7 3.5 14.9 10.2 9.8 4.7 13.7 5.9 5.8 7.1 4.6 9.1 10.4 5.8 6.9 10.9 8.6 7 5.9 6.8 11.6 8.3 16.1 5.1 10.6 7.9 12.7 8.4 13.2 10.7 13.2 10.6 0.6 4.1 8.4 1.5 4.9 9.3 4.9 1.4 4.7 2-Hydroxy-3-methyl-pentanoic acid 26.7 25.4 21.9 25.5 21.9 25.7 29.4 22.2 24.9 26 22.9 26.4 14.9 21.4 21.3 13.8 47.2 12.4 44.5 18.2 15.8 60 18.6 17.8 19.7 10.9 16.6 79.5 17 34.8 35.5 7.6 26.7 24.6 13.2 10.1 11.9 14.4 31.4 14.5 21.2 22.9 9.1 2-Hydroxybutyric acid 100.2 82.7 53.6 47.3 65.7 88.2 64.5 43.9 50 69.5 70.5 36.7 42.1 50.7 105.8 38.1 68.8 89.9 63.1 70.7 57.9 91.8 87.6 61.2 156.6 79.2 108.5 104.4 78.7 94 108.5 64.3 134.3 89.6 31.2 44.4 85.9 22.8 53.9 77.1 38.6 42.7 39.8 Ketoisovaleric acid 1.1 1 1.5 1 2.6 1.8 1.7 0.3 1.8 1.8 0.3 0.9 9.5 10.7 14.7 7 8.7 11.1 10.1 13.6 9.9 17.1 18 12.1 19.1 14.3 15.4 15.7 21 19.2 21.3 20.4 21.9 16.3 6.1 9.4 8.7 4 6 10 6.9 8.3 10.4 3-Hydroxybutyric acid 232.5 295.2 212 138.8 38.2 805.9 100.4 87.9 416.6 95.7 279.5 59.6 38.2 74.8 450.2 26.3 323.2 65.9 232.7 131.1 108.2 362.9 160.4 305.5 72.3 202.2 118.9 52.7 149.3 46.6 73.2 107.9 57.1 140.1 47.8 70.1 264.3 33.1 257.5 110.4 27.2 40.9 58.8 3-Hydroxyisobutyric acid 30.9 39.1 33.1 31.3 36.3 24.5 30 26 36.7 37.4 26.9 28.4 4.1 5 9.2 4.6 5.6 7.8 7.7 5.2 5.1 35.2 29.8 24.9 39.2 24.8 30.6 32.3 31 32.5 47.7 28.7 45.4 30 18.5 8.2 14.2 27.2 20.7 13.3 8.4 13.4 21.2 3-Methyl-2-oxovaleric acid 7.7 3.1 6 3.8 6.4 8.8 5.7 6.4 4.3 8.7 7.3 4.3 14.8 19 25.8 12.9 19.5 19.5 16.9 22.2 18.9 33.8 24.7 20.5 37.4 21.1 26.7 29.3 21 31.4 37.6 25.8 42.6 31.3 9.9 11.9 14.8 8.7 7.4 14.8 12 19.8 14.7 Acetic acid 248.4 240.5 242.2 262 355 227.5 320.1 250.2 253 284.6 258.9 243.1 50.1 58 53.4 50.4 55.8 48.8 59.9 74.1 57.5 368.2 411.4 366.7 396.4 354.6 515.1 329.1 356.8 343.4 414 302.8 305.8 310.2 45.7 60.5 48.4 45.7 56.7 53.3 49.2 64.2 63 CAR 2:0 14.8 18.2 12.3 13.2 7.2 12.5 9.5 7.8 16.8 13.8 10.2 10.4 8.8 11.3 12.7 11.2 14.3 15.2 16.1 9.7 10.3 13.3 9.1 4.8 12.7 8 3.6 9.6 5 12.7 4 18.7 11.3 9.1 9.3 11.2 10.9 9.7 12.6 13 9.7 7.3 10.7 Alanine 422.3 432.8 318.1 327.8 413.8 312 522.7 382.3 435.8 604.4 320.5 358.8 301.5 481.9 485.6 465.2 400.7 393.3 396.9 401.9 336.8 458.7 551.5 456.9 811.6 461.4 498.5 912.1 632.2 924.9 705.6 604 817.6 539.9 271.7 413.4 478.3 459 486.6 301.4 531.8 354.3 379.7 Vitamin C 2 1.6 3.8 5.4 1 3.2 1.6 1 5.8 0 4.7 5 4.2 4.7 0.6 3.5 3.2 5.8 6.7 13.2 18.4 3.2 6.8 2.7 9.9 2 5 7.1 4.8 8.3 9.1 4.2 7.4 4.1 4.8 3.4 1 0.4 1.3 0 5.5 1.1 13.9 Asparagine 33.7 45 50.9 54.7 38.5 39.8 57 46.4 52.8 46.5 49.9 47.8 37.3 46.7 29.6 20.9 38.8 40.8 48.8 63.8 40.6 61 53.2 29.6 73.6 45.1 64.3 97.4 68.2 137.1 62.3 104.1 55.5 49.1 32.1 47.9 15.8 32.1 55.6 26.4 56.1 51 36.4 Betaine 20.2 27.4 24 28.9 22.8 45.2 38.4 31.3 54.2 44 49.5 35.2 19.5 35.1 17.8 31.7 45.7 49 15.8 25.8 38.9 113.1 49.1 13.5 46.6 33.1 59.9 65.1 29.5 60.4 49.8 49.3 57 54 16.4 32.2 15.2 22.4 46.5 38.1 14.3 19.4 40.7 Choline 9.1 10.6 9.7 9 11 7.9 10 8 16.2 14.2 9.8 10.6 6.8 11.7 9.1 8 14 14.5 9.3 7.6 10.5 19.6 18 9.8 16.2 9.1 18.5 27.2 21.4 22.4 24.5 26 16.2 18.7 6 11.9 9.1 10.6 15.6 13.7 10.8 7.1 14.7 Citric acid 140.2 152.4 150.8 134.7 74.7 134.5 116.3 93.5 158.9 149.1 141.6 128.5 100.4 159.2 162.6 105.1 133.2 148.6 137.3 104.4 104.5 203.3 155.5 130.8 145.4 177.4 211.4 201.8 165.7 247.7 205.9 205.9 172.3 161 122.5 136 152 104.4 165.3 141.6 99.5 75.3 115.8 Creatine 59.9 26.5 72.2 80.4 35.9 25.6 60.1 85.4 34.5 57.7 55.2 37.9 51.5 74 100.8 62.1 91.3 91.6 68.9 98.9 84.6 113.9 63.2 70.4 160.3 83.9 99.3 125.5 99.3 136.2 108.6 122.8 142.3 132.4 53.4 79.9 93 54.6 101.7 69 87.1 90.9 103.9 Creatinine 82.7 55.5 69.8 98.6 108.3 68.6 62.7 61.6 76.2 73.3 54.8 61.4 66.7 85.6 61.2 86 64.2 91.2 76 74.1 76.5 122.9 124.8 94.9 131.2 99.1 76.1 155.4 85.3 150.8 106.8 141.5 103.1 116 66.3 80.5 58.8 62.9 62.6 72.4 77.3 55.1 76.3 Dimethylamine 5.3 7.2 1.6 1 5.3 5.8 6.6 1.6 7.9 5.5 8.8 0.5 3.2 1.6 2.4 6.3 5 2.1 1.9 5.1 1.9 2.6 2.4 5.6 1.8 8.5 1.4 2.4 1.3 7.3 1.9 1.1 1.8 8.9 1.4 0.6 2.7 3.8 4.3 1.7 0.8 3.8 1.5 Dimethylglycine 2.2 4.9 2.2 3.2 2.9 3.3 2.7 2 3 3.2 3.2 1.8 2.2 3.2 3.2 2 6.8 3.8 2.3 2.7 2.6 6 10.7 1.7 3.3 3.5 4.6 3.1 4.3 5.8 4.6 4.9 5.5 4.3 3.7 2.9 2.6 2.3 7.2 5.2 2.7 3.2 4.4 Dimethyl sulfone 15.7 8.5 9 9.7 4.6 9.3 7.7 8.1 14.9 13.9 10.4 8 5 8.8 5.7 4.3 7 4.9 8.8 4 7 12.1 12 13.4 20.6 12 15.8 16.9 12.8 15.2 13.8 8.2 12 11.7 3.8 10.9 4.9 3.3 6.9 5.1 10.6 4 8.1 Formic acid 30.4 29.4 31.4 33 29.7 32.9 33.4 36.1 37.6 31.2 34.6 32.5 28.1 35.9 31.9 30.6 36.6 31.5 31.3 31 28.5 256.4 288 160 529.6 282.9 296.3 406.9 353.5 412 223.2 484.5 269.6 425.5 23 36.2 39.5 37 44.5 30 41.9 35.4 36.9 Glucose 6205.9 4455.8 4000.3 5618.5 5563.7 4293.6 5027.8 4628.2 5360.5 6122.7 4768.6 4758.8 4525.6 4985.3 6877.1 5018.6 4416.9 7046.2 5221.3 5949 5101 6320.7 8141.3 5760.9 13202.4 5880.6 5542.2 7458.7 6112.3 8653.2 9953.9 7589.8 11296.2 6280.4 4386.2 5315.3 6739.4 4109.8 4566.5 4950.9 5648.9 5905.6 6232.9 Glutamine 424.5 594.4 457.9 586.5 343.9 463.2 685.8 591.9 665.3 544 497.4 556.5 466.6 566.6 381.7 588.9 486.3 510.5 461.7 507.3 578.8 988.7 663.1 503.8 919.2 437.2 706.4 1091.4 424 832.9 447.2 884.8 866 884.1 495.7 574.2 358 445.5 502.5 437.1 433.5 431.3 575.9 Glycerol 158.6 194.7 159 136.5 113.9 117.6 100.1 93.3 117.5 164 132 156 143.5 162.1 341.6 181.5 134.4 254.7 183.4 117.7 152 274.1 207.6 227.7 212.6 304.9 263.1 218 211.1 98.7 179.8 191 78.3 154.2 102 135.5 233 242.2 232.7 221 142.2 161.2 140 sn-Glycero-3-phosphocholine 40.1 45.8 42 54.8 44 31.8 57.1 41 67.1 61.9 33.5 46.1 36.5 51.5 29 44.4 38 40.9 36.4 34.2 40.7 102.7 92.2 45.4 73 66.3 108.8 83.9 49.6 72.9 91.8 72.5 72.3 68.1 37.1 55 29.4 39.5 42.3 39.7 41.3 30.8 46.3 Glycine 119.2 233.5 466.1 309.7 124.1 212.8 299.2 266 241.3 303.4 309.5 204.1 266 278.2 115.8 408.3 255 178.7 181.6 176.7 177.4 300.8 305.4 196.6 449.4 371.7 282.2 393.6 200.4 469.2 276.1 813.7 202.9 463 320.7 264.9 125.1 344.6 286.2 166.8 209.4 186.3 187 Histidine 56.4 81.5 55.3 74.4 34.1 62.9 76.1 76 77.2 76.2 65.5 66.5 53.7 70.4 60.4 68.9 63.1 78.1 108.8 89.1 69.1 111.5 105.8 53.5 153.5 91.8 46.3 145.1 112.6 109.3 62.6 125.8 138 114 74.9 67.8 68.6 48.6 59.7 70.5 84.6 101.1 72.5 Inosine 7.7 1.2 5.1 6 7 0.3 14.1 12.6 11.2 0 9.2 5.1 4.7 11.5 3.3 9.2 1.1 6.3 3.7 8.3 6.9 10.9 9 4.1 8.1 9.5 0.1 1.7 5.9 0 18.1 4 14.1 10.9 0 0 0 0 0 0 0 0 0 Isobutyric acid 11.6 6.8 6.1 6 8 7.2 5.4 3.9 5.8 9.1 4.7 2.8 8.6 9.5 15.3 5.1 8.4 9 7.7 13.1 5 14.7 10 5.7 13.1 9.2 11.1 11.8 11.7 17.8 11.7 7.1 12.4 15 6.4 8.2 13 8.9 6.7 10 8.4 7.9 7.5 Isoleucine 60.9 75.3 54.4 50.2 65.7 49.9 77.4 54.2 66.2 66.3 58.3 55.7 50.4 77.8 80.2 55.7 62.5 92.3 71.2 75.6 77 106.9 85.5 55.2 103.1 65.6 78.8 154.2 92.7 89.8 123.9 72.3 115 117 47 69.6 72 39 64.1 73 90.6 76.3 74.4 Isovaleric acid 18.7 22.3 16.2 18.9 17.8 14.5 16.4 17.3 25.4 23.2 13 21 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Ketoleucine 4.3 3 3.4 4.1 3.5 5.4 6.1 4.5 4.5 3.2 5.7 6.3 24.1 28.8 32.6 25.4 29.5 37.7 31.7 38.2 33.2 45.3 26.2 21.8 45.3 30.5 39.3 31.5 28.5 37 41.4 37.9 53.4 33.9 16.4 15.7 13.2 13.6 15.9 15 11.4 22.5 19.7 Lactic acid 3259.5 2881.3 2023.5 2743.7 3862 2202.7 3428.6 2286.2 2359.1 3454.3 2457.4 1445.7 1175.9 2925.8 3542.2 2084.2 1794 1878.3 1648.7 1293.4 1749 2916.7 5687.5 3105.7 4219.8 3040.5 5336.8 5061.8 3439.7 5325.7 5024.6 6517.8 5272.1 3008.4 874.8 1136.2 2355.6 1268.7 1833.6 1019.9 1704.3 887.5 1220.8 Leucine 125.3 169.4 115.8 104.1 147.4 98.3 154 111.4 148.6 137 107.5 114.2 107.3 141 142.8 115.8 127.1 184.1 134.8 151.9 148.9 201.2 164.8 121.4 227.2 151.3 201.3 260.3 192.2 197.2 240.9 173.1 236.6 198.9 122.8 147.6 130.5 98.7 145.5 170.2 148.9 160.6 163.4 Lysine 157.6 178.2 170.8 183 137.6 116.6 215.9 174.5 168.3 226.7 115.1 178 141.4 174.2 160.6 173.6 184.1 211.1 159.6 207.9 203.2 264.3 166.6 103.1 235.3 160.1 127.8 298.5 208.2 215 141 188.8 246 191.9 140 160.4 138.3 148.1 202.4 162.4 165.1 173.4 217.3 Mannose 70.4 54.3 54.4 64.6 109.8 62.3 46 55.4 76.5 60.4 50.1 63 54.3 58.2 77.3 46.9 54.2 55.3 77.3 76.7 87.2 91.3 104.8 53.6 89.1 52.6 96.4 70.7 64.4 62.9 87.2 62.4 87.5 76.6 59 64.4 70.6 37.8 53.1 43.8 46.5 59.3 85 Myo-inositol 67.2 37 38.8 45 43.5 44.9 35.9 30.4 68.4 36 35.2 42.1 27.1 30.5 32 36.3 37.2 36.3 27.8 25.6 32.8 59.2 53.7 52 52 85.3 46 63 53 62.7 49.4 51.8 50.1 38 13.4 44.3 23.2 42.1 27.8 45.1 43.8 29.7 57.9 Ornithine 54.9 92.2 73.7 81.1 73.8 80.3 87.9 69.9 93.8 116.6 75.7 77.3 66.4 72.4 43.7 70.6 70.4 91.8 43.3 67.4 74.4 81.8 76.6 35.9 52.7 59.1 45.8 150.1 62 93.8 41.8 125.7 65.8 100.6 65.9 58.1 37.7 57.1 68 46.4 46.4 40.6 74.2 Phenylalanine 52.4 106 58.3 71.8 90.1 68 77.8 56.8 74.5 90.6 64.8 72 51.1 76.3 71.4 62.5 77.2 81.1 78.7 70.6 66.9 119.8 122.9 77.5 125.4 88.1 125.7 180.2 107 141.1 117.6 148.4 119.8 112.9 35.5 66.7 62.7 54.4 73.3 49.4 74 64.4 74.7 Proline 153 115.7 116.8 179.8 106.1 110.4 141.6 135.6 133.3 143.1 96 105.2 122 310.8 251.4 284.7 239.6 202.4 172.5 205.6 222.2 265.4 302.3 139.4 240.2 166.8 310.3 345.7 238.3 371.7 293.2 208.1 265.4 309.5 122.9 241.1 202.6 217.6 182.8 138.5 154.8 187.8 196.8 Propylene glycol 5.2 0.5 2.6 0.5 12.7 1.2 4 7.1 3 2 2.9 1.7 5.9 9.4 4.9 2.6 5.2 6.1 7.3 5.8 6.7 8.7 7.5 3.9 3.7 8.2 3.9 9.9 10.9 7.4 6.8 5.4 1.3 4.7 3.9 10.2 4.5 6.2 17.4 8.4 8.6 6.9 1.9 Pyroglutamic acid 0 0 19.1 18.1 10.3 0 8.3 32.1 18.7 10.7 17.8 0 0 0 0 0 0 0 0 0 0 60.3 326.3 105.3 2.7 412 152.2 148.7 305.8 44.4 256.7 67.9 18.5 41.1 43.2 12.5 50.2 0 0 8.6 0 0 0 Pyruvic acid 3.1 2.5 2.1 0.8 4 1.4 2.3 2.9 3.1 2.3 1.4 0.6 33.4 51 69.7 36.6 31.9 26.4 41.2 20 18.1 49.6 69.5 34.9 40.8 69.1 21.1 34.8 56.9 113 74.1 55.3 90 22.8 23.9 39.6 67.8 29.8 34.8 24.5 53.7 30.2 46.5 Serine 164 260.9 297.9 257 252 207.3 276.4 242.3 283.8 271.9 246.7 209.7 203.5 229.2 191.6 223 258.5 233.4 155.2 277.6 250.2 362.7 303.6 236.6 317.6 298.6 351.1 428.3 297.9 426.6 319.5 444 347.3 380.7 222.7 196 166 177.6 283.8 179.6 172 258.7 242.5 Threonine 73.1 124 141 111.1 101.4 79.1 114.2 112.3 112.7 92.8 98.8 88.6 81.8 76 102.1 91.8 141.9 101.3 130.8 144.6 134 162.8 160 132.3 130 106.2 162.8 198.6 196.8 208.2 124.2 174.8 122.6 159.7 124.9 101.8 91.9 55.4 160.4 73 126 123.9 109 Tryptophan 9.3 29.5 23.6 34.8 30 23 28.1 27.6 33.9 38.2 20 26.8 41.1 52.2 37.8 53.6 45.2 43.5 45.3 55.5 48.9 68.4 63.2 26.9 75.7 34.8 65 97.3 47.4 88.9 83.1 56.1 88.1 76.9 46.2 20.1 21.7 27 31.6 21.2 11.8 43 30.5 Tyrosine 42.9 81.2 45.7 57.5 73.5 53.9 68.8 48.1 93.9 64.3 66.8 48.6 51.6 80.3 56.8 56.9 65.8 76.4 54.7 55.4 73.4 73.9 74.2 52.8 101.9 79.6 70.7 156.9 72.6 165.1 106.9 93.2 105.9 111 66.1 68.5 54.5 64.9 74.5 76.6 63.8 53.2 81.3 Valine 238.1 308.1 212.9 194.6 252.8 176.5 284.3 204.4 231.5 278.3 197.7 209.7 221.6 277.2 271.8 197.2 204.2 334.9 235.1 273.5 278.2 308.3 314.6 186.9 379.5 240.2 305.8 447.9 335.6 343.3 339.4 280.8 374.2 349.6 212.1 269.9 252.8 166.7 210.1 278.2 220.1 251.4 287.7 NMR_METABOLITE_DATA_END #METABOLITES METABOLITES_START metabolite_name HMDB PubChem ChEBI KEGG METLIN SMILES 2S-Aminobutyric acid HMDB0000452 80283 35619 C02356 12 CC[C@H](N)C(O)=O 2-Hydroxy-3-methylbutyric acid HMDB0000407 99823 60645 NA 5396 CC(C)C(O)C(O)=O 2-Hydroxy-3-methyl-pentanoic acid HMDB0000317 10796774 89228 NA 5306 CC[C@@H](C)[C@@H](O)C(O)=O 2-Hydroxybutyric acid HMDB0000008 440864 50613 C05984 3783 CC[C@H](O)C(O)=O Ketoisovaleric acid HMDB0000019 49 16530 C00141 5091 CC(C)C(=O)C(O)=O 3-Hydroxybutyric acid HMDB0000011 441 17066 C01089 NA C[C@@H](O)CC(O)=O 3-Hydroxyisobutyric acid HMDB0000023 440873 37373 C06001 483 C[C@@H](CO)C(O)=O 3-Methyl-2-oxovaleric acid HMDB0000491 439286 15614 C00671 5478 CC[C@H](C)C(=O)C(O)=O Acetic acid HMDB0000042 176 15366 C00033 3206 CC(O)=O CAR 2:0 HMDB0000201 7045767 57589 C02571 5213 CC(=O)O[C@H](CC(O)=O)C[N+](C)(C)C Alanine HMDB0000161 5950 16449 C01401 11 CC(N)C(O)=O Vitamin C HMDB0000044 54670067 29073 C00072 3753 [H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO Asparagine HMDB0000168 6267 17196 C00152 14 N[C@@H](CC(N)=O)C(O)=O Betaine HMDB0000043 247 41139 C00719 287 C[N+](C)(C)CC(O)=O Choline HMDB0000097 305 15354 C00114 56 C[N+](C)(C)CCO Citric acid HMDB0000094 311 30769 C00158 124 OC(=O)CC(O)(CC(O)=O)C(O)=O Creatine HMDB0000064 586 16919 C00300 7 CN(CC(O)=O)C(N)=N Creatinine HMDB0000562 588 16737 C00791 8 CN1CC(=O)NC1=N Dimethylamine HMDB0000087 674 17170 C00543 3758 CNC Dimethylglycine HMDB0000092 673 17724 C01026 277 CN(C)CC(O)=O Dimethyl sulfone HMDB0004983 6213 9349 C11142 7236 CS(C)(=O)=O Formic acid HMDB0000142 284 30751 C00058 3202 OC=O Glucose HMDB0000122 5793 15903 C00031 133 OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O Glutamine HMDB0000641 5961 18050 C00064 5614 N[C@@H](CCC(N)=O)C(O)=O Glycerol HMDB0000131 753 17754 C00116 105 OCC(O)CO sn-Glycero-3-phosphocholine HMDB0000086 657272 16870 C00670 370 C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO Glycine HMDB0000123 750 15428 C00037 20 NCC(O)=O Histidine HMDB0000177 6274 15971 C00135 21 N[C@@H](CC1=CN=CN1)C(O)=O Inosine HMDB0000195 6021 17596 C00294 84 OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C(O)N=CN=C12 Isobutyric acid HMDB0001873 6590 16135 C02632 106 CC(C)C(O)=O Isoleucine HMDB0000172 6306 17191 C00407 5193 CC[C@H](C)[C@H](N)C(O)=O Isovaleric acid HMDB0000718 10430 28484 C08262 109 CC(C)CC(O)=O Ketoleucine HMDB0000695 70 48430 C00233 5663 CC(C)CC(=O)C(O)=O Lactic acid HMDB0000190 107689 422 C00186 5205 C[C@H](O)C(O)=O Leucine HMDB0000687 6106 15603 C00123 24 CC(C)C[C@H](N)C(O)=O Lysine HMDB0000182 5962 18019 C00047 5200 NCCCC[C@H](N)C(O)=O Mannose HMDB0000169 185698 28729 C00159 NA OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O Myo-inositol HMDB0000211 NA 17268 C00137 5221 O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O Ornithine HMDB0000214 6262 15729 C00077 27 NCCC[C@H](N)C(O)=O Phenylalanine HMDB0000159 6140 17295 C00079 28 N[C@@H](CC1=CC=CC=C1)C(O)=O Proline HMDB0000162 145742 17203 C00148 29 OC(=O)[C@@H]1CCCN1 Propylene glycol HMDB0001881 259994 28972 C00583 3220 C[C@@H](O)CO Pyroglutamic acid HMDB0000267 7405 18183 C01879 3251 OC(=O)[C@@H]1CCC(=O)N1 Pyruvic acid HMDB0000243 1060 32816 C00022 117 CC(=O)C(O)=O Serine HMDB0000187 5951 17115 C00065 5203 N[C@@H](CO)C(O)=O Threonine HMDB0000167 6288 16857 C00188 32 C[C@@H](O)[C@H](N)C(O)=O Tryptophan HMDB0000929 6305 16828 C00078 5879 N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O Tyrosine HMDB0000158 6057 17895 C00082 34 N[C@@H](CC1=CC=C(O)C=C1)C(O)=O Valine HMDB0000883 6287 16414 C00183 5842 CC(C)[C@H](N)C(O)=O METABOLITES_END #END